Immune checkpoint inhibitors (ICIs) are considered a new standard-of-care across many
cancer indications. This review provides an update on ICIs approved by the Food and Drug …

Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed
to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T …

Importance Programmed cell death (PD-1) and programmed cell death ligand 1 (PD-L1)
inhibitors have been increasingly used in cancer therapy. Understanding the treatment …

Background Immune checkpoint inhibitors targeting PD-1 have shown clinical benefit in
adults with cancer, but data on these drugs in children are scarce. We did a phase 1–2 study …

Importance Effective treatment options are limited for patients with advanced, metastatic
esophageal cancer progressing after 2 or more lines of systemic therapy. Objective To …

Programmed cell death protein 1 (PD-1) blockade targeting the PD-1 immune checkpoint
has demonstrated unprecedented clinical efficacy in the treatment of advanced cancers …

Monoclonal antibodies targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), programed cell
death 1 (PD-1), or its ligand (PD-L1) have become the mainstay for advanced malignancies …

CD19-directed chimeric antigen receptor–modified (CAR T) T cells achieve durable
remissions in about 30% to 40% of relapsed/refractory large B-cell lymphomas. T-cell …

Background Phenotypic characterization of immune cells in the bone marrow (BM) of
patients with acute myeloid leukemia (AML) is lacking. Methods T‐cell infiltration was …

PURPOSE Patients with relapsed or refractory primary mediastinal large B-cell lymphoma
(rrPMBCL) have a poor prognosis, and their treatment represents an urgent and unmet …